I was going on and on about the importance of clinical trials for perspective aging therapies, and there you go - a large study of metformin is being planned under the supervision of Nir Barzilai from Albert Einstein College of Medicine.
"The trial aims to test the drug metformin, a common medication often used to treat Type 2 diabetes, and see if it can delay or prevent other chronic diseases."
But most importantly this trial may pave the way to official recognition of aging as a disease or a condition that needs treatment. This will be a real gamechanger.
"Sandy Walsh, an FDA spokeswoman, said the agency’s perspective has long been that “aging” isn’t a disease. “We clearly have approved drugs that treat consequences of aging,” she said. Although the FDA currently is inclined to treat diseases prevalent in older people as separate medical conditions, “if someone in the drug-development industry found something that treated all of these, we might revisit our thinking.”
I really wish this trial will receive enough funding so that we all benefit from its results. So far only the planning stage has been funded. The importance of this work is hard to overestimate - our lives probably depend on this trial.